
Oncology NEWS International
- Oncology NEWS International Vol 23 No 5
- Volume 23
- Issue 5
Entries Are Sought for Kushner Writing Award
BETHESDA, Md--The American Medical Writers Association is seeking applications for the 1996 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer.
BETHESDA, Md--The American Medical Writers Association is seekingapplications for the 1996 Rose Kushner Awards for Writing Achievementin the Field of Breast Cancer.
Categories include articles (newspapers and magazines, or scientificjournals), books (medical and lay), brochures and monographs,and scripts for video, film, or radio (medical and lay audi-ences).The winning entry in each category is awarded $1,000, providedthrough a grant from Zeneca Pharmaceuticals.
Entries must be received by May 10, 1996. For information, writeto the Rose Kushner Award Committee, American Medical WritersAssociation, 9650 Rockville Pike, Bethesda, MD 20814-3998. Phone301-493-0003 or fax 301-493-6384.
Articles in this issue
over 30 years ago
Earlier Unrelated BMT Is Effective in CML Subgroupover 30 years ago
Taxol/Cisplatin Extends Survival in Advanced Ovarian Caover 30 years ago
Prostate Cancer Patients Face a Host of Psychosocial Issuesover 30 years ago
NSABP to Study Docetaxel in Operable Breast Cancerover 30 years ago
Panel Recommends Approval of Talc for Malignant Pleural Effusionsover 30 years ago
ODAC Recommends Approval of Verluma for Staging of SCLCover 30 years ago
Minorities Lack Internet Access to Cancer Research Dataover 30 years ago
Fludarabine Produces CRs as First-Line CLL Therapyover 30 years ago
Managed Care: The View From Salick Managed CareRelated Content


107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)


109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR



















































